Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01412944 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 43
- Enrollment target
NCT01412944 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT01412944, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 43 participants
- Enrollment target
Study Summary
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
Interventions
- DRUG secukinumab 150mg
- DRUG secukinumab 10mg/kg i.v. regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01412944
The ClinicalTrials.gov registry entry for NCT01412944 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which secukinumab 150mg is the first listed.
NCT01412944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01412944 about?
NCT01412944 is a clinical study titled "Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis". The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.
What is the current status of trial NCT01412944?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 43 participants. The study started on 2011-12. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01412944?
The interventions under investigation include: secukinumab 150mg (DRUG), secukinumab 10mg/kg i.v. regimen (DRUG).
Who is sponsoring clinical trial NCT01412944?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.